Enterosys participates in the opening meeting of the LEARN project

Non-alcoholic liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (which includes abdominal obesity, hyperglycemia, dyslipidemia and hypertension), and the leading cause of liver disease. NAFLD, like the metabolic syndrome, is a strong predictor of the development of type 2 diabetes. NAFLD includes a spectrum of liver diseases such as steatosis, or fatty liver disease, characterized by an accumulation of lipids in the liver. Steatosis is a benign pathology but predisposes to severe forms such as inflammatory steatosis (steatohepatitis or NASH) that can lead to the deleterious stages of cirrhosis and liver cancer. NAFLD affects a significant proportion of the world’s population and is recognized as a major public health issue. All metabolic pathologies constitute important risk factors for cardiovascular morbidity and mortality through the occurrence of myocardial infarction and stroke.

The diagnosis of inflammatory forms of NAFLD (NASH) requires liver biopsies, invasive approaches associated with risks of bleeding. Moreover, the factors and mechanisms involved in the transition from one stage of the disease to another are not clearly identified. Various clinical trials of therapeutic molecules are underway but there are no drugs available for the treatment of NAFLD. Lifestyle interventions are the best treatment for NAFLD, but these behavioral changes are difficult to achieve and maintain over time.

Therefore, relevant preclinical models are needed to elucidate the factors and mechanisms involved in NAFLD and to identify predictive biomarkers for this disease. Epidemiological studies demonstrate a link between metabolic liver disease and a diet high in fat and sugar. The nutritional composition of carbohydrate and/or lipid diets influences the occurrence of metabolic pathologies. Different diets leading to the development of NASH (high fat diet, western diet) by mimicking this type of diet are available in animal experiments. Recent studies show that the quality of dietary proteins can also influence the development of NASH, with whey proteins playing a protective role against this pathology.

Non-alcoholic liver diseases have an impact on metabolic and endocrine disturbances and on blood coagulation. This project associates three teams with complementary expertise in these fields and a company from the Occitanie region and Enterosys, a young company that wishes to develop its expertise in this field.

Research

Categorie

Archives

Gut microbiota: the key to understanding health and disease

Did you know that trillions of microorganisms are working behind the scenes in your body to keep you healthy? Often called our “hidden organ,” the gut microbiota is an extraordinary ecosystem that influences much more than just digestion.  How does this invisible...

Intestinal barrier : key to digestion and nutrient absorption 

Unlock the mystery of your digestive system!  In this edition, we explore the vital roles of digestion and nutrient absorption, essential for maintaining health. Digestion is the process by which foods are broken down into smaller molecules, or nutrients, making them...

gut-health : the key to general health

Have you ever wondered how your body turns the food you eat into the energy you need? The secret lies within the fascinating world of gut physiology. Your digestive tract is not just a simple tube for digestion—it’s a complex system designed to absorb essential...

Teambuilding Enterosys

On January 11th and 12th, 2024, the Enterosys team came together for a dynamic event designed to strengthen team cohesion, celebrate achievements, and set a vision for the future. This gathering was not only an opportunity to reflect on the...

Salon BioFIT 2023

Join us for Salon BioFIT2023 where we'll come together to foster a sens of community, collaboration and success. Let's meet !Booking plateform link Maybe you can also like : Foodtech innovative research boosted with gut and gut-brain axis